Sun Pharmaceutical Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Mon Apr 06 2026

Sun Pharmaceutical Industries (NSE: SUNPHARMA) is preparing to announce its fourth quarter FY26 (Q4 FY26) financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 19, 2026 to approve the audited financial statements for Q4 FY26 and consider a recommendation for a final dividend for FY26 shareholder approval.

With Sun Pharmaceutical Industries trading at a current market price of Rs 1,640 — down from a 52-week high of Rs 1,958 and a 1-year return of -3% — the Q4 FY26 results will be a pivotal moment for investors deciding whether to hold, add, or reduce their position. Analyst estimates for Q4 FY26 revenue stand at Rs 14,500–15,500 Cr, with PAT expectations of Rs 2,900–3,200 Cr and margin projections of EBITDA 28–30%.

This article covers the Sun Pharmaceutical Industries Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions ahead of the announcement. For real-time research and expert analysis, access Sun Pharmaceutical Industries data on Univest.

Table of Contents

Sun Pharmaceutical Industries Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Sun Pharmaceutical Industries has scheduled its Q4 FY26 results for May 19, 2026. The board of directors will meet to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026. The trading window for designated employees is closed until 48 hours after the results announcement, as per SEBI regulations. Mark May 19, 2026 as a key date in your investment calendar if you hold or track Sun Pharmaceutical Industries.

Company	Results Date	Key Watch
TCS	April 9, 2026 (Confirmed)	Deal TCV, EBIT margin, FY27 guidance
Infosys	April 23, 2026 (Confirmed)	Revenue guidance, attrition, large deals
Sun Pharmaceutical Industries	May 19, 2026 (Expected)	US specialty growth 12–15% YoY

Why This Quarter Matters

Q4 FY26 is the quarter ending March 31, 2026 — the final quarter of the financial year — and carries additional significance for investors. It determines the full-year FY26 financial performance, sets the benchmark for FY27 estimates, and triggers final dividend announcements. For Sun Pharmaceutical Industries, specifically, Q4 FY26 matters because: the stock has delivered a -3% 1-year return against a backdrop of macro uncertainty, making the quarter’s growth trajectory crucial for sentiment recovery.

Institutional investors typically rebalance portfolios at the end of March, and the Q4 results give them the clarity needed to assess whether to increase or reduce positions ahead of the new financial year. Analyst price targets for Sun Pharmaceutical Industries — ranging from Rs 1,900 to Rs 2,100 — will be updated post-results based on the actual Q4 FY26 performance and the management’s FY27 guidance.

Sun Pharmaceutical Industries Q4 FY26 Earnings Estimates

Sun Pharmaceutical Industries Q4 FY26 analyst estimates — Revenue, PAT, Margin, Growth

Access premium research and analyst estimates on Univest.

Brokerages including MOFSL, YES Securities, JM Financial, and others have published their Q4 FY26 preview estimates for Sun Pharmaceutical Industries. The consensus expects Rs 14,500–15,500 Cr in revenue for Q4 FY26, compared to Rs 13,897 Cr in Q3 FY26. Profit after tax (PAT) is estimated at Rs 2,900–3,200 Cr, with margin expectations of EBITDA 28–30%. Growth momentum on the key volume/activity metric is projected at US specialty growth 12–15% YoY.

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Key Driver
Revenue	Rs 14,500–15,500 Cr	Rs 13,897 Cr	Volume + pricing
PAT	Rs 2,900–3,200 Cr	Rs 2,980 Cr	Margin expansion
Margin	EBITDA 28–30%	EBITDA ~29%	Cost efficiency
Growth Metric	US specialty growth 12–15% YoY	Previous quarter	Demand recovery
Dividend	Rs 8–10 per share	—	Capital allocation

Beyond the headline numbers, investors will watch closely for: management commentary on FY27 revenue growth guidance, any revision in margin trajectory, updates on order book or deal pipeline, and capex or investment plans. A positive surprise on any two of these four parameters could drive a meaningful post-results re-rating.

Screen Sun Pharmaceutical Industries fundamentals and historical financials on Univest Screener.

5 Key Factors That Will Drive Sun Pharmaceutical Industries Q4 FY26 Performance

1. Revenue Momentum and Q4 FY26 Seasonal Strength

Sun Pharmaceutical Industries enters Q4 FY26 — the quarter ending March 31, 2026 — with expectation of seasonal pickup in revenues. Analysts project revenue of Rs 14,500–15,500 Cr for Q4 FY26, compared to Rs 13,897 Cr in Q3. Q4 is typically a seasonally stronger quarter for Pharma companies due to year-end spending patterns, project closures, and government order execution. Management’s ability to convert the backlog into recognised revenue will be the primary variable determining whether Sun Pharmaceutical Industries meets, beats, or misses the consensus.

2. Profitability and Margin Trajectory

Sun Pharmaceutical Industries’s PAT is estimated at Rs 2,900–3,200 Cr for Q4 FY26, with margin expectations at EBITDA 28–30%. Analysts are watching the interplay between revenue growth and cost pressures — including employee costs, input material pricing, and technology investments. If Sun Pharmaceutical Industries can hold or expand margins while delivering the estimated revenue, it would mark a continuation of the profitability improvement seen over FY26. Brokerage targets ranging from Rs 1,950 to Rs 2,100 suggest meaningful analyst divergence on the precise earnings path.

3. Volume Growth and Market Share

Sun Pharmaceutical Industries’s Q4 FY26 performance on the volume or growth metric (US specialty growth 12–15% YoY) will be a key indicator of market share dynamics in the Pharma sector. Sector-wide, Q4 FY26 is expected to show demand recovery supported by improved consumer sentiment, government spending, and resolution of near-term macroeconomic headwinds. Sun Pharmaceutical Industries’s ability to maintain or expand its competitive position will determine whether the FY27 growth story is compelling.

4. FY27 Guidance and Management Commentary

Beyond the quarterly numbers, the management’s outlook commentary and formal FY27 guidance will be the most market-moving element of Sun Pharmaceutical Industries’s Q4 FY26 results announcement. Investors and analysts will scrutinise every word of the earnings call transcript for signals on revenue growth expectations, capex plans, margin trajectory, and any strategic pivots. A confident, upward-revised FY27 guidance could drive a 5-10% post-results stock re-rating.

5. Dividend and Capital Allocation

Sun Pharmaceutical Industries is expected to consider or recommend a dividend of Rs 8–10 per share at the Q4 FY26 board meeting. For income-oriented investors, the dividend announcement signals management’s confidence in future cash flow generation. A higher-than-expected dividend would also support the stock price by improving yield attractiveness. Capital allocation decisions — including buybacks, capex commitments, and acquisition strategy — will also inform how the market values Sun Pharmaceutical Industries’s FY27-28 earnings trajectory.

5 Risks to Watch in Sun Pharmaceutical Industries Q4 FY26

1. Macro Headwinds — West Asia Conflict and Crude Oil Spike

The West Asia conflict has driven crude oil above $100 per barrel, creating input cost pressure for companies in energy-intensive sectors and dampening consumer sentiment. If the conflict persists, it could weigh on India’s growth outlook for FY27, reducing business investment and consumer spending — both of which affect Sun Pharmaceutical Industries’s demand environment.

2. US Tariff Uncertainty and Global Trade Disruption

The US tariff regime changes in 2025-26 have created uncertainty for Indian exporters and IT services companies dependent on US client spending. Sun Pharmaceutical Industries’s Pharma exposure may be directly or indirectly affected if US corporate cost-cutting accelerates in response to higher import tariffs.

3. Revenue Miss Risk and Earnings Guidance Disappointment

Sun Pharmaceutical Industries’s Q4 FY26 results carry downside risk if execution is weaker than consensus. A revenue miss of 3-5% could trigger a 5-8% post-results stock decline, particularly given the sensitivity of the current market environment to negative earnings surprises. Margin misses of 50-100 basis points would compound the negative reaction.

4. Competition and Market Share Erosion

The Pharma sector remains highly competitive, with both domestic and international players investing aggressively. Sun Pharmaceutical Industries faces pricing pressure from competitors and risk of market share erosion if product innovation or service quality falls short of customer expectations. Any loss of key customer relationships or contracts could materially impact Q4 and FY27 revenue.

5. Regulatory and Compliance Risk

Companies in the Pharma sector face evolving regulatory requirements. Any new SEBI, RBI, or government regulation that increases compliance costs or restricts business practices could adversely affect Sun Pharmaceutical Industries’s profitability and operational flexibility. Investors should monitor regulatory announcements in the sector alongside quarterly results.

Sun Pharmaceutical Industries Share Price and Analyst Ratings

Sun Pharmaceutical Industries is trading at Rs 1,640 as of early April 2026, against a 52-week high of Rs 1,958 and a 52-week low of Rs 1,440. The market capitalisation stands at Rs 3,94,000 Cr. The 1-year return of -3% reflects the broader Pharma sector headwinds alongside company-specific factors. The Q4 FY26 results and FY27 guidance will be critical in determining whether the stock can recover toward analyst consensus targets.

Brokerage	Rating	Target Price	Thesis
MOFSL	Buy	Rs 2,100	Specialty US pipeline strongest in Indian pharma
YES Securities	Buy	Rs 2,050	Global specialty now 32% of revenue
JM Financial	Buy	Rs 1,950	Taro stabilisation + India brand growth
CLSA	Outperform	Rs 1,900	Premium justified on R&D pipeline depth

Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries’s live price and receive real-time Q4 result alerts when the board declares the results on May 19, 2026.

Conclusion

Sun Pharmaceutical Industries Q4 FY26 results on May 19, 2026 will be a key event for investors monitoring the Pharma sector. Analysts project PAT of Rs 2,900–3,200 Cr and revenue of Rs 14,500–15,500 Cr, representing continued sequential growth from Q3 FY26 levels. At a CMP of Rs 1,640 and with analyst targets ranging from Rs 1,900 to Rs 2,100, the stock offers meaningful risk-reward for informed investors. FY27 guidance commentary will be the most critical post-results catalyst.

This analysis is based on publicly available analyst estimates and company filings. Actual Q4 FY26 results may differ materially from consensus estimates. Market reactions to results depend not only on the reported numbers but also on management guidance, peer performance, and broader macro sentiment. Investing ahead of quarterly results carries earnings risk — the stock can fall on a miss or rise sharply on a beat.

For more Q4 FY26 previews across IT, banking, auto, pharma, and cement sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Sun Pharmaceutical Industries Q4 results 2026 date?

Sun Pharmaceutical Industries Q4 FY26 results are expected on May 19, 2026. The board of directors will meet on this date to approve the audited financial statements for the quarter ended March 31, 2026, and consider a final dividend recommendation for FY26.

What is the Sun Pharmaceutical Industries Q4 FY26 PAT estimate?

Analysts estimate Sun Pharmaceutical Industries’s Q4 FY26 PAT at Rs 2,900–3,200 Cr. This compares to Q3 FY26 PAT of Rs 2,980 Cr. Key brokerages including MOFSL, YES Securities, and JM Financial have published these estimates. Actual results may differ.

What is Sun Pharmaceutical Industries’s share price ahead of Q4 results?

Sun Pharmaceutical Industries is trading at Rs 1,640 as of early April 2026. The 52-week high is Rs 1,958 and the 52-week low is Rs 1,440. The market capitalisation is Rs 3,94,000 Cr. The 1-year return stands at -3%. Track the live share price on Univest.

Will Sun Pharmaceutical Industries declare a dividend in Q4 2026?

Sun Pharmaceutical Industries is expected to consider a dividend of Rs 8–10 per share at the Q4 FY26 board meeting on May 19, 2026. This would be the final dividend for FY26. The actual dividend amount depends on the board’s assessment of profitability, capital adequacy, and future investment needs.

Which analysts have a Buy rating on Sun Pharmaceutical Industries?

MOFSL (target Rs 2,100), YES Securities (target Rs 2,050), JM Financial (target Rs 1,950), CLSA (target Rs 1,900) have Buy/Outperform ratings on Sun Pharmaceutical Industries as of April 2026. hold Neutral ratings. All targets and ratings are subject to revision after Q4 FY26 results.

What were Sun Pharmaceutical Industries Q3 FY26 results?

Sun Pharmaceutical Industries reported Q3 FY26 (October–December 2025) revenue of Rs 13,897 Cr and PAT of Rs 2,980 Cr, with margin at EBITDA ~29%. The Q3 FY26 results provided the base against which Q4 FY26 estimates have been built by analysts.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. For the full TCS Q4 results preview, visit the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the full Infosys Q4 Results 2026 preview on Univest Blogs for detailed estimates, analyst ratings, and FY27 guidance expectations.

Is Sun Pharmaceutical Industries a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Sun Pharmaceutical Industries has both compelling factors — Specialty US pipeline strongest in Indian pharma — and genuine near-term risks. Analyst consensus targets range from Rs 1,900 to Rs 2,100. Consult a SEBI-registered financial advisor before making any investment decision. Use Univest Screener to assess Sun Pharmaceutical Industries fundamentals independently.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.